

Name of the issue: Emcure Pharmaceuticals Limited

1	Type of issue (IPO/ FPO)	IPO
2	Issue size (Rs. in crore)	1,952.00
3	Grade of issue alongwith name of the rating agency	
	Name	
	Grade	Not Applicable
4	Subscription Level (Number of times) ⁽¹⁾	48.14
	<i>Source: Minutes for Basis of Allotment dated July 8, 2024</i>	
	<i>(1) Figure is after technical rejections</i>	

5 QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) On Allotment July 8, 2024	5.10%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	6.87%
(iii) at the end of 1st FY (March 31, 2025)*	N.A.
(iv) at the end of 2nd FY (March 31, 2026)*	N.A.
(v) at the end of 3rd FY (March 31, 2027)*	N.A.

*will be updated in due course

6 Financials of the issuer (consolidated basis)

(Rs. Million)

Parameters	31-Mar-25	31-Mar-26	31-Mar-27
Revenue from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid up equity share capital	Not Available	Not Available	Not Available
Other Equity	Not Available	Not Available	Not Available

Note: Financials for the year ended March 31, 2025, March 31, 2026 and March 31, 2027 shall be updated in due course

7 Trading status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2025) ⁽¹⁾	Not Available
(ii) at the end of 2nd FY (March 31, 2026) ⁽¹⁾	Not Available
(iii) at the end of 3rd FY (March 31, 2027) ⁽¹⁾	Not Available

(1) will be updated in due course

8 Change, if any, in directors of issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2025 ⁽¹⁾	Not Available	
During year ended March 31, 2026 ⁽¹⁾	Not Available	
During year ended March 31, 2027 ⁽¹⁾	Not Available	

(1) Change in Directors of Issuer is not updated as the relevant financial years have not been completed

9 Status of implementation of project/ commencement of commercial production

Particulars	Remarks
(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	Not Applicable

10 Status of utilization of issue proceeds

Particulars	Amount which will be financed from Net Proceeds	Estimated Utilisation of Net Proceeds	
		FY 2025	FY 2026
Rs. in Million			
(i) as disclosed in the offer document			
Repayment/ prepayment, in full or in part of certain outstanding borrowings availed by the Company	6,000	6,000	
General corporate purposes	1588.64	1191.48	397.16
Total	7588.64	7191.48	397.16

(ii) Actual utilization Fully utilised

(iii) Reasons for deviation, if any None

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	None
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	None
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	None

12 Price-related data

Designated SE	NSE
Issue Price (Rs.)	1008
Listing Date	July 10, 2024

Price parameters	At close of listing day-July 10, 2024	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day	As at the end of March 31, 2025		
				Closing price during FY	High during FY	Low during FY
Market Price	1359.15	1,289.65	Not Available	Not Available	Not Available	Not Available
Nifty 50	24,324.45	24,117.00	Not Available	Not Available	Not Available	Not Available
Price parameters	As at the end of March 31, 2026			As at the end of March 31, 2027		
		Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY
Market Price	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Nifty 50	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

Source: Stock Exchange data. Where the 90th day/ March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	Face Value (Rs.)	As disclosed in the offer document	At the end of 1st FY March 31, 2025**	At the end of 2nd FY March 31, 2026**	At the end of 3rd FY March 31, 2027**
EPS	Issuer: Consolidated ⁽¹⁾	10	27.54	-	-	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	334.59			
	Cipla Limited	2	51.01			
	Alkem Laboratories Limited	2	150.19			
	Torrent Pharmaceuticals Limited	5	48.94			
	Mankind Pharma Limited	1	47.68			
	Abbott India Limited	10	565.28			
	J. B. Chemicals & Pharmaceutic	1	34.85			
	Industry Avg		176.08			
P/E	Issuer: Consolidated	10	36.6	-	-	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	17.93			
	Cipla Limited	2	30.1			
	Alkem Laboratories Limited	2	33.86			
	Torrent Pharmaceuticals Limited	5	57.74			
	Mankind Pharma Limited	1	45.3			
	Abbott India Limited	10	47.43			
	J. B. Chemicals & Pharmaceutic	1	50.49			
	Industry Avg		40.41			
RoNW%	Issuer: Consolidated ⁽³⁾	10	16.87%	-	-	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	19.74%			
	Cipla Limited	2	15.43%			
	Alkem Laboratories Limited	2	17.41%			
	Torrent Pharmaceuticals Limited	5	24.15%			
	Mankind Pharma Limited	1	20.43%			
	Abbott India Limited	10	32.48%			
	J. B. Chemicals & Pharmaceutic	1	18.90%			
	Industry Avg:		21.22%			
	Issuer: Consolidated ⁽⁴⁾	10	163.22	-	-	-
	Peer Group:					
	Dr. Reddy's Laboratories Limited	5	1693.75			
Cipla Limited	2	330.78				

NAV per share	Alkem Laboratories Limited	2	862.46
	Torrent Pharmaceuticals Limited	5	202.57
	Mankind Pharma Limited	1	233.73
	Abbott India Limited	10	1740.17
	J. B. Chemicals & Pharmaceutic	1	188.37
	Industry Avg:		750.26

(1) Diluted earnings per share (in Rs.) = Diluted EPS refers to the diluted earnings per share of the respective company

(2) P/E: P / E Ratio has been computed based on the closing market price of equity shares on BSE on June 21, 2024, divided by the Diluted EPS for the year ended March 31, 2024

(3) RoNW is computed as profit attributable to owners of the company divided by Total Equity attributable to the owners

(4) Net Asset Value per Equity Share is computed as the closing net worth divided by the equity shares outstanding as on March 31, 2024

**Not available as the relevant fiscal year has not been completed / information not disclosed

14 Any other material information

Particulars	Date
Emcure Pharmaceuticals Limited ("Emcure"), together with its subsidiary, Gennova Biopharmaceuticals Limited ("Gennova"), has entered into a Share Subscription and Shareholders' Agreement dated July 25, 2024 to acquire 26% of Sunsure Solarpark Twelve Private Limited	July 25, 2024
For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com	